Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer (GrandP/SPCG19)
A Randomized, Open-label, Multicenter, Parallel Group Treatment, Phase 3, Two-arm Study to Measure the Effect on Overall Survival and Quality of Life of Immediate Curative Therapy Compared With Standard Conservative Treatment in Older Male Participants Aged ≥ 75 Years With Non-metastatic, High-risk Prostate Cancer
Sponsor: Klinbeforsk
A PHASE3 clinical study on Prostate Cancer, this trial is actively recruiting participants. The trial is conducted by Klinbeforsk and has accumulated 10 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE3
-
Nov 2024 — Aug 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Klinbeforsk
- Oslo University Hospital
- Sven Löffeler
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Copenhagen, Denmark , Drammen, Norway , Esbjerg, Denmark , Hamar, Norway , Helsinki, Finland , Kristiansand, Norway , Lørenskog, Norway , Odense, Denmark , Oslo, Norway , Skien, Norway and 8 more locations